The news. The narrative. The timeline.
Coinbase posted a $1.49 loss against a 27-cent profit consensus, missed subscription revenue by $35 million, and printed the layoff two days before the call as the strategy, not the response.
Novo's pill is a record-breaking start at $354M and 2M scripts; Lilly's Foundayo prints week four into a 24-to-1 ratio and an RBC bar of 90,000 fills by week 12.
Adjusted EPS of $0.85 against $0.68 consensus, Cash App accelerating, FY guide raised — and a $309 million GAAP loss the bitcoin remeasurement explains.
Three days after Disney's Q2 print, no sell-side note has named the FCC ABC-license cliff in cautionary language, and the four-document SEC architecture stands.
Three days post-print, the JPM/GS/BofA spread on AMD has not converged, and the AMD-Meta and AMD-OpenAI warrant cohort sits as the precedent the SpaceX S-1 inherits at T-7.
Cerebras's lead bookrunners are requiring limit-only orders at the $115-$125 band as the IOI book holds above $10 billion at roughly 3x oversubscription.
T-7 to the public S-1 window — and the prospectus inherits Tesla's $573 million cross-revenue plus the Brockman trial's open question about disclosure under oath.
Three days after the print, Pfizer's full-year guide assumes no 2026 buybacks against $3.3B unused — the most aggressive disciplined-capital line in pharma.
Week four came in at 7,335 — a 31 percent increase off the 5,612 baseline, and still on the wrong side of the math that gets Lilly to a $1.4 billion FY model.
Apple's $0.27 dividend records May 11, pays May 14 — and Berkshire's Q1 13F drops May 15, putting the disciplined-cohort frame on a single calendar.
Lionsgate's Q4 + FY26 earnings land May 21 — T-13 — making the only U.S. pure-play scaled studio the test case against Disney's FCC cliff and Paramount-WBD.